|Day Low/High||119.28 / 121.97|
|52 Wk Low/High||72.67 / 128.57|
Depending on your risk appetite, it makes sense to keep it light heading into this weekend.
Jim Cramer looks at the latest biotech deals as Cubist acquires Trius amid changes among Biotech companies.
Jim Cramer looks at the pop in Alexion on rumors of Roche deal, and why this deal makes sense.
There have been some really good winners this year. By Bob Lang One of the best sectors to play this year has been the biotechs and I would be remiss if I didn't tell you my best play ever was just a couple weeks ago with Onyx Pharmaceutical (ONXX),...
Brittany Umar and Scott Redler, chief strategic officer at T3Live.com, reveal how to trade stocks ahead of earnings season: retail, banks, tech.
Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken
Charts of Actavis and Alexion show a combination of positive technical factors.
Here's another batch of names with impressive free cash flow, a crucial metric.
This metric is a prime indicator of financial health, and these health-related stock stand out.
These large-cap companies have topped expectations for four quarters and are projected to again report robust earnings.
The entire sector did well withstanding Tuesday's decline, but here are a few standouts.